ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

THE ROLE OF LABORATORY DIAGNOSTICS IN EARLY DETECTION OF EMERGING INFECTIOUS DISEASES

Bhawna Suryawanshi[1], Arif Hussain[2] Hardik Guriaya[3]

[1]*Assistant Professor, Swami Vivekanand Group of Institutes, Ramnagar, Banur*
[2]*BSC MLS, SEM-6, Department of Paramedical, Sviet, Banur*
[3]*Microbiologist*

ABSTRACT

The early detection of emerging infectious diseases is a cornerstone of global health preparedness, with laboratory diagnostics playing a crucial role in this process. As infectious diseases evolve and spread rapidly due to globalization and environmental changes, the need for robust diagnostic systems has become increasingly urgent. Laboratory diagnostics offer the tools to identify, monitor, and control pathogens, often before symptoms are fully visible. Techniques such as PCR, genomic sequencing, and serological assays have significantly enhanced our ability to detect diseases early. These technologies enable the identification of novel pathogens and provide crucial insights into their transmission patterns, virulence factors, and potential public health impact.

In addition to molecular diagnostics, advancements in microfluidics and point-of-care testing have revolutionized the accessibility and speed of pathogen detection. These innovations are especially critical in resource-limited areas where outbreaks often begin but go unnoticed due to a lack of infrastructure. By integrating laboratory diagnostics with Early Warning Systems (EWS), public health agencies can track disease outbreaks in real time, enabling timely interventions that limit the spread of emerging diseases.

The integration of advanced diagnostic techniques with global surveillance systems highlights the indispensable role of laboratories in managing infectious diseases. In this review, we will explore the advancements in diagnostic technologies and their application in early detection, illustrating how they have shaped global health strategies in preventing pandemics. The future of laboratory diagnostics will likely focus on further innovations in rapid, decentralized testing and improved global collaboration to combat the rising threat of emerging infectious diseases.

INTRODUCTION

The role of laboratory diagnostics in the early detection of emerging infectious diseases (EIDs) is pivotal to mitigating their global health impact. Emerging infectious diseases are those that have either newly appeared or are rapidly increasing in incidence or geographic spread, posing a significant threat to both developed and developing nations. The need for timely identification of these diseases is critical to control their spread, initiate effective treatments, and implement public health interventions. Laboratory diagnostics play a central role in this process, providing the tools needed for early pathogen detection, characterization, and monitoring, which are essential for outbreak control and prevention.

One of the fundamental diagnostic techniques used for early detection is molecular diagnostics, particularly Polymerase Chain Reaction (PCR) and its variants like RT-PCR. These methods enable the amplification and detection of viral or bacterial genetic material, making them highly sensitive tools for identifying pathogens in their early stages of infection. PCR was crucial during the SARS, MERS, and COVID-19 outbreaks, allowing laboratories to rapidly diagnose patients, track disease progression, and evaluate the effectiveness of public health interventions. Next-generation sequencing (NGS) has also emerged as a powerful diagnostic tool, providing detailed insights into pathogen genomes, which is critical for identifying novel strains and monitoring mutations that may affect transmissibility or treatment efficacy.

In addition to molecular diagnostics, serological tests such as enzyme-linked immunosorbent assays (ELISA) have proven useful in detecting the presence of antibodies, indicating past or present infection. These tests are particularly valuable for population-level screening and epidemiological studies, helping health authorities understand disease spread and immunity levels within communities. Moreover, the development of point-of-care diagnostics has revolutionized the accessibility of early detection, especially in low-resource settings where laboratory infrastructure may be limited. Devices such as microfluidic chips allow for rapid, on-site testing of infectious agents, providing quick results and enabling immediate action to prevent further spread.

Another critical aspect of laboratory diagnostics is its integration with global surveillance systems. Emerging infectious diseases often require real-time monitoring to detect outbreaks early and respond effectively. Laboratory data, when incorporated into Early Warning Systems (EWS), enable health authorities to

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

identify patterns of infection and predict potential outbreaks before they reach epidemic or pandemic levels. This was evident in the early stages of the Ebola and COVID-19 outbreaks, where laboratory data played a critical role in guiding public health responses and shaping policy decisions.

Despite significant advancements in diagnostic technologies, challenges remain, particularly in resource-limited settings where access to sophisticated laboratory infrastructure is often inadequate. Moreover, the rapid evolution of pathogens, such as the mutation of viruses like SARS-CoV-2, requires continuous development of diagnostic assays to keep pace with the changing nature of infectious agents. The integration of new technologies, such as CRISPR-based diagnostics and artificial intelligence (AI), offers promising avenues for improving the speed, accuracy, and scalability of laboratory diagnostics.

1. Diagnostic Techniques in Early Detection

The early detection of emerging infectious diseases (EIDs) is supported by various diagnostic techniques that offer rapid and reliable identification of pathogens, which is crucial for timely intervention and disease control. These techniques have evolved significantly, enhancing our ability to identify pathogens at the onset of an outbreak.

Molecular Diagnostics

Molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), are pivotal in early detection due to their high sensitivity and specificity. PCR, including RT-PCR for RNA viruses, allows for the amplification of viral genetic material, enabling the quick and precise identification of pathogens in their early stages of infection. This method has been instrumental in controlling outbreaks like COVID-19 and MERS by facilitating rapid diagnosis and allowing health systems to implement timely quarantine and treatment measures. NGS complements PCR by providing in-depth genetic information on pathogens, which is essential for tracking mutations and understanding transmission dynamics. For instance, NGS played a crucial role in identifying SARS-CoV-2 variants, informing both public health strategies and vaccine development.

Serological and Immunological Tests

Enzyme-Linked Immunosorbent Assay (ELISA) and rapid antigen tests are also central to early detection, particularly in assessing the immune response and the spread of infection. ELISA can detect antibodies specific to a pathogen, offering insights into infection rates and immunity within a population. This method was used extensively during the HIV and Zika outbreaks to monitor immunity levels and guide public health interventions. Rapid antigen tests, while less sensitive than PCR, provide immediate results and are thus valuable for large-scale screening, particularly in low-resource settings where laboratory capacity may be limited.

Point-of-Care Testing (POCT)

POCT devices, such as microfluidic chips and lateral flow assays, facilitate on-site testing and rapid results, which are particularly beneficial for early detection in remote areas. The accessibility of these devices enables immediate action in response to detected cases, helping to prevent further spread, especially in areas where traditional laboratory infrastructure is inadequate. Research underscores the value of POCT in providing critical data on infection status, enabling real-time response and supporting broader public health efforts.

CRISPR-Based Diagnostics

Emerging CRISPR-based diagnostic technologies, like SHERLOCK and DETECTR, have demonstrated significant potential for the detection of emerging pathogens. These technologies harness CRISPR systems to identify specific genetic sequences with high accuracy and speed, making them suitable for the rapid diagnosis of newly emerging diseases. CRISPR-based diagnostics offer flexibility and scalability, as they can be quickly adapted to detect new pathogens, an essential feature in the early stages of an outbreak.

Biosensors and Wearable Devices

Finally, advancements in biosensor technology have enabled the development of wearable devices that monitor physiological markers continuously. These biosensors can detect early signs of infection, such as changes in respiratory rate or body temperature, allowing for proactive disease management. As technology advances, the integration of biosensors into public health systems could further enhance early detection capabilities by providing real-time data on potential infections.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

Technology and tools in Diagnosis Process



The diagnostic process in healthcare increasingly relies on advanced technology and tools, with health information technology (health IT) playing a pivotal role. Tools like Electronic Health Records (EHRs), clinical decision support systems, and telemedicine are essential components of this process, enabling efficient data collection, analysis, and sharing. Health IT systems facilitate comprehensive patient data capture, including clinical histories, physical examinations, and diagnostic test results, which aids clinicians in making informed decisions. However, despite their benefits, challenges such as interoperability issues and the fragmentation of health IT systems continue to impede seamless information exchange, potentially impacting diagnostic accuracy and timeliness.

Recent advancements have expanded the scope of these tools, introducing mobile health (mHealth) applications and wearable diagnostic devices that allow for remote monitoring and personalized care. These innovations hold promise for expanding diagnostic access, particularly in remote or underserved areas. Yet, as these technologies grow in use, there are also concerns related to data privacy, system integration, and the overall reliability of health information technology in clinical practice. Addressing these challenges through continuous improvement in system interoperability and usability will be essential for maximizing the potential of health IT to support accurate and timely diagnoses.

Challenges in Implementing Diagnostic Solutions

Implementing diagnostic solutions in healthcare is met with various challenges, primarily stemming from technological, logistical, and systemic issues. One significant challenge is interoperability between different health information systems. With diverse diagnostic tools and electronic health records (EHRs) often operating on incompatible platforms, the seamless exchange of patient data becomes difficult. This fragmentation can hinder diagnostic accuracy and delay timely decision-making, as clinicians may not have access to a patient's comprehensive medical history.

Data privacy and security are also major concerns, particularly as mobile health (mHealth) and wearable diagnostic technologies become more prevalent. Ensuring the secure transfer and storage of sensitive health information remains a pressing issue, especially given the increasing sophistication of cyber threats. In addition, adoption and integration of new diagnostic technologies can be hindered by financial and infrastructural constraints. Many healthcare facilities, especially those in resource-limited settings, face budget restrictions and lack the necessary infrastructure to support advanced diagnostic tools, which may require significant upfront investments in equipment and staff training.

Impact of Laboratory Diagnostics on Public Health Policy

Laboratory diagnostics significantly influence public health policy by providing essential data for disease monitoring, prevention, and control. Accurate diagnostic testing allows health authorities to identify and understand the prevalence of diseases, enabling them to make informed decisions regarding resource allocation, disease surveillance, and emergency response measures.

One of the critical roles laboratory diagnostics play in public health policy is through disease surveillance and outbreak detection. By rapidly identifying pathogens, diagnostics allow for timely responses to emerging health threats. For example, during the COVID-19 pandemic, diagnostic testing was pivotal for tracking the spread of the virus, which directly influenced policies on lockdowns, travel restrictions, and vaccination rollouts. Effective surveillance not only aids in responding to outbreaks but also in preventing them by informing vaccination strategies and other preventive measures.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

Laboratory diagnostics also inform health policy decisions on a national and international level by contributing to epidemiological data that shapes policies related to infectious disease control, immunization programs, and public health interventions. For instance, routine testing for diseases like tuberculosis and HIV provides insights into infection rates and guides policymakers on where to focus public health resources. Additionally, diagnostics aid in the management of antimicrobial resistance (AMR) by identifying drug-resistant pathogens, helping to shape policies that promote the responsible use of antibiotics and other antimicrobials.

Lastly, laboratory diagnostics support public health research and innovation, enabling scientists to study disease trends and the effectiveness of public health interventions. This evidence base is crucial for developing guidelines and protocols that improve health outcomes on a broader scale. As laboratory technology continues to advance, its role in shaping evidence-based public health policies becomes even more integral, driving improvements in healthcare quality and access.

Case Studies of Successful Early Detection through Diagnostics

1. Tuberculosis

Tuberculosis (TB) is a leading infectious disease that causes over 1.5 million deaths globally each year. Laboratory diagnostics have played a vital role in early detection and control, especially with the advent of the GeneXpert MTB/RIF test, which detects TB and rifampicin resistance in just two hours. This rapid diagnostic approach has significantly improved case detection rates, particularly in high-burden areas like India, where more than 10 million tests have been conducted. Early identification of multidrug-resistant TB (MDR-TB) allows for timely and targeted treatment, reducing transmission and improving outcomes, highlighting the importance of accessible and accurate diagnostics in global TB control.


TABLE 1.1 CASE DEFINITIONS BY SITE AND BACTERIOLOGICAL STATUS IN HIV-NEGATIVE ADULTS AND FOR NON-HIV PREVALENT SETTINGS

Case classification	Definition
Pulmonary tuberculosis, sputum smear-positive (PTB+)	One or more initial sputum smear examinations positive for Acid-fast bacilli by microscopy
Pulmonary tuberculosis, sputum smear-negative (PTB–)	A case of pulmonary tuberculosis who does not meet the above definition for smear-positive tuberculosis. **Note:** In keeping with good clinical and public health practices, diagnostic criteria should include: 1. At least two sputum specimens negative for acid-fast bacilli, **and** 2. Radiographic abnormalities consistent with active pulmonary tuberculosis, **and** 3. No response to a course of broad-spectrum antibiotics, and 4. Decision by a clinician to treat with a full course of anti-tuberculosis chemotherapy. This group includes patients whose sputum smears are negative but whose culture is positive.
Extrapulmonary tuberculosis	A patient with tuberculosis affecting organs other than the lungs. Diagnosis should be based on one culture-positive specimen, or histological or strong clinical evidence consistent with active extrapulmonary tuberculosis, followed by a decision by a clinician to treat with a full course of anti-tuberculosis chemotherapy.

2. COVID -19

During the COVID-19 pandemic, South Korea's rapid implementation of PCR and antigen testing exemplified the critical role of diagnostics in controlling disease spread. By March 2020, South Korea was conducting over 20,000 PCR tests daily, enabling prompt identification and isolation of cases, which contributed to a significantly lower mortality rate compared to global averages. The WHO recognized South Korea's approach as effective in reducing transmission, as it combined PCR for accuracy with antigen tests for quick results in resource-limited settings. This testing strategy influenced global health policies and highlighted the importance of rapid diagnostics in managing infectious disease outbreaks, underscoring the need for robust testing frameworks to detect and control future pandemics.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188



3. HIV/AIDS

The HIV/AIDS epidemic underscores the importance of diagnostic advancements in public health. From the early days of ELISA and Western blot tests for initial detection, diagnostics evolved to include rapid tests, which significantly improved access to HIV testing globally, especially in resource-limited regions like sub-Saharan Africa. This increased testing helped boost awareness, with WHO reporting that by 2021, around 84% of people with HIV knew their status. Advanced tools like viral load tests and CD4 counts have since transformed HIV/AIDS into a manageable chronic condition, guiding antiretroviral therapy (ART) and improving patient outcomes. These developments highlight how diagnostics shape public health strategies, enabling earlier intervention and more effective disease management.

4. Cholera

Deadly disease called cholera is caused by eating contaminated food and water etc. The primary cause of this syndrome is an enterotoxin (cholera toxin). In stool specimens V. Cholerae can be easily identified by its characteristic yellow colonies.

Cholera is an acute secretory diarrheal illness caused by toxinproducing strains of the Gram-negative bacterium Vibrio cholera . Severe cholera is characterized by profound fluid and electrolyte losses in the stool and the rapid development of hypovolemic shock, often within 24 h from the initial onset of vomiting and diarrhea.

- Stool test observed under microscope.




Figure 1: In Stool test *Vibrio cholerae* bacteria's are look like this.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

- Hematology investigation of cholera.

Complete Blood Cells Count test (CBC)

In this test report some blood deficiency identified and weak patient's defense system (**Table 1**).


Test	Value	Units	Expected value
Hb%	12.3	g/dL	13 to 18
WBC	6067	mm_3 new born	5500 to 18000/cm
Platelet count	616000	mm_3	150000 to 400000
Different Leucocyte count (DLC)			
Neutrophils	22	%	45 to 75%
Lymphocytes	70	%	20 to 45%
Eosinophils	4	%	02 to 06%
Monocytes	4	%	02 to 10%
RBC	4.3	10>12/L	3.5 to 5.5
MCV	79.2	F1	75 to 100
HCT	36.2	%	35 to 55
MCH	26.5	Pg	25 to 35
ESR	24		Upto 12

Table 1: Different component values of blood were compared with their normal values.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

5.Malaria

Malaria remains a significant public health concern, especially in sub-Saharan Africa, where 95% of cases are reported. According to the World Health Organization (WHO), there were approximately 241 million malaria cases and over 627,000 deaths globally in 2020. Laboratory diagnostics have been critical in the early detection and management of malaria, particularly in endemic regions. Rapid Diagnostic Tests (RDTs) are widely used to identify malaria quickly by detecting specific antigens in a patient's blood, allowing for timely treatment. Microscopy remains the gold standard for malaria diagnosis, enabling healthcare workers to confirm the presence and type of Plasmodium parasites that cause the disease. These diagnostics are crucial in reducing the burden of malaria by facilitating prompt treatment, which lowers transmission and helps prevent severe complications.



CONCLUSION

Laboratory diagnostics are critical for early detection of emerging infectious diseases because they provide accurate information that helps with disease surveillance ,treatment ,and prevention:

Disease Surveillance

Laboratory data helps predict outbreaks and differentiate between background events and true outbreaks.

Treatment

Early detection allows for proper treatment to be instituted.

Prevention

Laboratory data helps with the development of control and prevention practices.

Outbreak Response

The Coalition for Epidemic Preparedness Innovations (CEPI) and others are working to ensure that rapid response mechanisms are in place to address emerging infectious diseases.
Accurate diagnosis helps identify the source of an outbreak so that appropriate health measures can be taken.

Vaccine Development

Clinical assays that measure the immune response and presence of pathogens are used to license vaccine products. Laboratories report new or unusual pathogens to help establish a specific etiology for disease syndromes.

Specimen Handling

Specimens must be handled appropriately, transported safely, and accompanied by clinical and epidemiological information.

Reagent Availability

The range of diagnostic tests a laboratory can perform is limited by reagent availability.

Staff Training

Staff must be trained to conduct the technically demanding tests required to identify new pathogens.

Quality Control

Quality control and proficiency tests are essential to ensure the quality of results.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 1| January 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402 || ISI Value: 1.188

Biosafety
The laboratory must have the appropriate biosafety containment conditions to safely test pathogenic organisms.

Communication
Results must be communicated promptly to medical staff and epidemiological monitoring programs.

Specimen Archiving
A systematic program to archive clinical specimens can help recognize new strains or changing incidence patterns.

REFERENCE

1. *Luan J, Ba J, Liu B, Xu X, Shu D. 2021–2022 monitoring, early warning, and forecasting of global infectious diseases. Int. J. Biosaf. 2022;4(2):98–104. Link.*
2. *Li X, Cui W, Zhang F. Who Was the First Doctor to Report the COVID-19 Outbreak in Wuhan, China? J Nucl Med. 2020;61(6):782–3. Link.*
3. *Economist. The pandemic's true death toll The Economist: The Economist; 2021. Available from: https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates.*
4. *World Health Organization. 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021. World Health Organization; 2022. Available from: https://www.who.int/news/item/05-05-2022-14.9-million-excess-deaths.*
5. *European Centre for Disease Prevention and Control. Risk assessment: Monkeypox multi-country outbreak 2022. ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-monkeypox.*
6. *Hu SN, Cheng X, Chen D. Comparative study on early warning methods of infectious diseases. InE35 Web of Conferences; 2021. P. 03084. Link.*
7. *Bath PA. Health informatics: current issues and challenges. J. Inf. Sci. 2008;34(4):501–18. Link.*
8. *Teutsch SM, Thacker SB. Planning a public health surveillance system. Epidemiol. Bull. 1995;16(1):1–6. Link.*
9. *Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Link.*
10. *Chase V. ProMED: a global early warning system for disease. Environ. Health Perspect. 1996;104(7):699. Link.*
11. *Toubiana L, Flahault A. A space-time criterion for early detection of epidemics of influenza-like-illness. Eur J Epidemiol. 1998;14(5):465–70. Link.*
12. *Leining LM, Short K, Erickson TA, Gunter SM, Ronca SE, Schulte J, et al. Syndromic Surveillance among Evacuees at a Houston "Megashelter" following Hurricane Harvey. Sustainability. 2022;14(10). Link.*
13. *Ansaldi F, Orsi A, Altomonte F, Bertone G, Parodi V, Carloni R, et al. Syndrome surveillance and molecular epidemiology for early detection and tracing of an outbreak of measles in Liguria, Italy. J Med Virol. 2009;81(10):1807–13. Link.*
14. *Cashmore AW, Muscatello DJ, Merrifield A, Spokes P, MacArtney K, Jalaludin BB. Relationship between the population incidence of pertussis in children in New South Wales, Australia and emergency department visits with cough: A time series analysis. BMC Medical Inform. Decis. Mak. 2013;13(1). Link.*
15. *Elliot AJ, Hughes HE, Hughes TC, Locker TE, Shannon T, Heyworth J, et al. Establishing an emergency department syndromic surveillance system to support the London 2012 Olympic and Paralympic Games. Emerg. Med.: EMJ. 2012;29(12):954–60. Link.*
16. *World Health Organization. World Malaria Report 2022. World Health Organization; 2022. Available from: https://www.who.int/publications/i/item/9789240064898.*
17. *Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020;368(6489):395-400. Link.*
18. *The Lancet. Dengue surveillance and tracking system. Lancet Inf. Dis. 2018;18(4):369. Link.*
19. *Obermeyer Z, Emanuel EJ. Predicting the future — Big data, machine learning, and clinical medicine. N Engl J Med. 2016;375:1216-9. Link.*
20. *Binnicker MJ. Can rapid PCR testing of respiratory samples improve patient outcomes? Clin. Microbiol. Newsl. 2020;42(24):197–202. Link.*
21. *Gonzalez JP, Saluzzo JF, Le Guenno B, Leroy E. Emerging viral diseases. Med Trop. 1995;55(1):43–7. Link.*
22. *Centers for Disease Control and Prevention. Cholera — Vibrio cholerae infection. CDC; 2023. Available from: https://www.cdc.gov/cholera/general/index.html.*
23. *Castro KG, Jaffe HW. The HIV/AIDS epidemic: 40 years in the making. The Lancet 2021;397(10292): 1713-4. Link.*
24. *Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. Link.*
25. *World Health Organization. Laboratory testing for Middle East respiratory syndrome coronavirus: interim guidance. World Health Organization; 2013. Available from: https://apps.who.int/iris/handle/10665/117000.*